Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial - Concepedia

Concepedia

Publication | Closed Access

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial

132

Citations

22

References

2020

Year

Xavier Roblin, Nicolas Williet, Gilles Boschetti, Jean–Marc Phelip, Émilie Del Tedesco, Anne‐Emmanuelle Berger, Philippe Vedrines, Gérard Duru, Laurent Peyrin‐Biroulet, Stéphane Nancey,

Abstract

03580876.

References

	Year	Citations
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch, New England Journal of Medicine	2010	3.1K
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study Nicholas A. Kennedy, Graham Heap, Harry Green, The Lancet. Gastroenterology & hepatology InflammationActive Luminal CrohnAnti-tnf Treatment FailureImmunologyClinical Epidemiology	2019	655
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens, Gastroenterology InflammationDisease TreatedAutoimmune DiseaseImmunosuppressive TherapyImmunology	2008	494
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease Waqqas Afif, Edward V. Loftus, William A. Faubion, The American Journal of Gastroenterology	2010	486
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient Niels Vande Casteele, Ann Gils, Sharat Singh, The American Journal of Gastroenterology	2013	342
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease Shomron Ben‐Horin, Matti Waterman, Uri Kopylov, Clinical Gastroenterology and Hepatology InflammationChronic Inflammatory DiseasesAnti-inflammatoryAutoimmune DiseaseImmunology	2012	302
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab Bella Ungar, Yehuda Chowers, Miri Yavzori, Gut	2013	298
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease Niels Vande Casteele, Reena Khanna, Barrett G. Levesque, Gut	2014	283
The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful Shomron Ben‐Horin, Miri Yavzori, Lior H. Katz, Gut	2010	204
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases Xavier Roblin, Melanie Rinaudo, Émilie Del Tedesco, The American Journal of Gastroenterology	2014	189

Page 1